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Using USRDS generated mortality tables to compare local ESRD
mortality rates to national rates. Mortality tables of the U.S. Renal Data
System allow description of national mortality rates among prevalent
dialysis patients in five-year age groups and four major categories of
causes of ESRD for Black and White patients. Based on these tables
derived from over 50,000 deaths in dialysis patients during 1987 to 1989
a methodology is described that allows comparison of local or regional
mortality rates to national rates with determination of a standardized
mortality ratio and statistical significance. Since this methodology
adjusts for patient age, race and cause of ESRD, it can serve as a useful
tool for dialysis research and local quality assurance.
Outcome studies for patients with end-stage renal disease
(ESRD) have focused primarily on mortality rates from the start
of ESRD therapy to allow comparisons by diagnosis (such as
diabetic vs. non-diabetic), race, gender, age or treatment [1, 2].
With the development of the U.S. Renal Data System (USRDS)
[3], validated national U.S. data are available on at least 93% of
ESRD patients which allows assessment of national averages of
mortality rates for both patient cohorts starting ESRD therapy
and for prevalent patients alive at the beginning of a calender
year. The latter data serve as a reference for comparison
purposes in order to evaluate the mortality observed for a
specific group of ESRD patients. This paper describes such
reference tables and the method of comparing mortality ob-
served in a specific group of ESRD patients to the mortality that
would be expected on the basis of the rates for the U.S.
Medicare population of ESRD patients. This method, which
expands on rates published in the USRDS Annual Data Report
[2], adjusts for patient age, race, and diagnosis. Thus, any
differences revealed by this method between the observed and
the expected mortality are attributable to factors other than age,
race, and diagnosis. This paper also describes the evaluation of
the statistical significance of an observed mortality difference.
Such adjusted comparisons to the national average could be
used to compare the mortality among patients at a specific
region or institution to that in the general ESRD population.
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Subsequent to such a comparison, institutions with higher than
expected mortalilty could seek to identify the sources of the
unexpected mortality by examining factors such as other pa-
tient characteristics or patterns of treatment. Similarly, institu-
tions with lower than expected mortality could be studied
further to identify the likely explanations for the lower mortal-
ity. Furthermore, under this methodology the ESRD population
of a foreign country can be treated as the comparison popula-
tion. Thus, an age, race, and diagnosis adjusted mortality rate
can be calculated for a foreign country and compared to the
U.S. rate.
Methods
The 1990 USRDS Annual Data Report (Table D.29) reported
on mortality rates by five-year age groups, two race groups
(Black, White) and four diagnosis categories (diabetes, hyper-
tension, glomerulonephritis, and other disease) for all patients
receiving dialysis at the beginning of 1988. There were few
patients, and fewer deaths in some of the patient subgroups,
leading to unstable estimates of the underlying death rate for
such patients. In order to improve the stability of the national
death rates for the present paper, data from three recent years
(1987—1989) have been pooled together to serve as a national
death rate reference (Table 1). Although death rates may have
changed slightly during this three-year period, the pooled death
rates can still be used to give an approximate comparative norm
for dialysis patients treated over any time interval during these
years. Similarly, since national ESRD mortality rates are rela-
tively stable over time, this Table could still be used with local
patient data from years more recent than 1989.
The death rates in Table 1 are specific by patient age, race,
and diagnosis. The "All" diagnosis category includes patients
for whom the USRDS is missing data on diagnosis, since it is
assumed that the dialysis unit (or other comparison locality) has
diagnosis information on virtually all of their patients. How-
ever, the "Other" diagnosis category excludes the patients for
whom the USRDS is missing data on diagnosis. The reason for
this exclusion is that the dialysis unit is much less likely to have
patients with missing diagnosis, and thus the dialysis unit's
"Other" category will only include patients with diagnoses
other than diabetes, hypertension, or glomerulonephritis.
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Table 1. ESRD death rates during 1987—1989 per 1,000 patient years at risk among patients alive on January 1, by age, primary disease, and
racea
Total dialysis
(ce
patients (never Tx) on J
nsored at first transplant)
anuary 1
Diagnosis
All Other
(includes missing (excludes missing
Age as of
Jan. 1
diag.) Diabetes
Black White
Hypertension
Black White
Glomerulonephritis
Black White
diag.)
Black WhiteBlack White
0-14b 60.6 48.0 — — — — — — — —
15_19b 52.7 40.5 — — — — — — — —
20—24 76.9 65.1 227.9 177.3 57.4 53.5 42.1 47.1 104.4 60.1
25—29 98.2 95.8 166.9 234.7 76.4 83.7 81.8 51.3 111.4 59.8
30—34 128.1 126.0 194.9 273.6 97.5 85.4 133.5 48.3 134.0 79.8
35—39 112.7 125.7 187.0 283.9 88.6 61.7 111.9 63.5 132.3 66.4
40—44 114.6 153.4 182.0 304.5 97.2 118.5 103.0 75.1 110.6 104.6
45—49 123.4 166.3 172.3 322.9 104.2 125.1 96.7 94.5 126.9 116.1
50—54 148.2 201.4 209.7 342.9 127.7 186.2 119.6 129.2 126.9 139.4
55—59 178.1 231.7 228.5 386.9 149.3 221.1 153.4 164.2 152.0 170.4
60—64 213.5 278.5 250.5 421.0 196.4 270.3 196.6 212.4 197.1 216.1
65—69 255.3 321.5 300.9 454.5 228.0 321.7 215.0 261.2 242.1 265.1
70—74 312.9 384.9 356.1 539.0 292.4 408.4 301.2 316.6 301.2 320.0
75—79 356.1 451.4 406.2 598.1 343.7 470.7 283.6 402.1 361.3 402.3
80—84 414.7 555.1 508.0 713.6 397.1 592.0 359.5 466.3 365.3 517.3
85+ 507.4 670.7 579.7 755.8 467.0 689.7 638.2 648.7 560.7 609.7
Total' 199.1 278.8 259.9 402.5 189.5 343.5 149.9 201.7 190.2 228.1
a The rates reported here are somewhat higher than the rates reported in the USRDS 1991 Annual Data Report due to a number of changes in
calculation (explained in more detail in the 1992 Annual Data Report). The rates reported here are more precise than previously reported rates.b Due to small cell sizes, rates for patients less than 20 years old are not diagnosis-specific.
'Overall death rate is 250.6 deaths per 1,000 patient years at risk (Black and White combined).
Therefore, including the USRDS patients with missing diagno-
sis in the "Other" diagnosis category would distort the rates for
this category.
Since cell sizes are particularly small for patients under 20
years of age, these patients have been categorized into two age
groups, 0 to 14 years of age, and 15 to 19 years of age.
Furthermore, rates are presented only for all disease groups
combined for patients under age 20, since disease-specific rates
were unstable.
Mortality rates are presented only for Black and White
patients. Patients of other races were excluded for several
reasons. There are insufficient cases to generate stable esti-
mates by age and diagnosis for racial groups other than Blacks
and Whites. Similarly, other racial groups were not included in
the "All" diagnosis category because of the expected hetero-
geneous effects of other racial groups, especially for Native
Americans and for Asians. It is expected that the former have
higher than average mortality, while the latter have lower than
average mortality. For dialysis units or regions of the country
with high concentrations of these two racial groups, mortality
comparisons using the methodology described here (which
includes "other" races) should be performed with caution:
reclassilying other races as Black or White can lead to distorted
estimates.
Each death rate is computed as the number of deaths ob-
served among corresponding ESRD patients receiving dialysis
on January 1, 1986, 1987, and 1988, divided by the sum of the
lengths of follow-up for each patient in the group. Note that this
is not the same as the fraction of the patients who died. For
example, across these years, among the 2681 White, diabetic
ESRD patients between the ages of 50 and 54 who were
receiving dialysis on January 1, there were 762 deaths. These
2681 patients contributed a total of 2197 years of time on
dialysis. The time on therapy starts on January 1 for each
patient and stops on the date of death, transplant, or December
31, whichever comes first. The death rate is computed as
762/2197 (deaths/patient years) and is different from the fraction
dead, that is, 762/2681 (deaths/patient), because not all of the
patients contribute a full year of dialysis therapy. In Table 1 the
death rate for each patient subgroup was multiplied by 1000.
Table 1 thus reports the expected number of deaths per 1000
patient years of dialysis therapy.
To compare mortality in a study group to the national rates,
the number of patient years of dialysis therapy must be com-
puted for each patient subgroup defined by age, race, and
diagnosis in the study group. Multiplying the number of patient
years of therapy in a subgroup by the corresponding national
death rate yields the expected number of deaths for that
subgroup of patients. After comparing the observed and ex-
pected mortality for each subgroup, summing the expected and
observed number of deaths across the patient subgroups gives a
comparison of the total number of observed deaths to the total
number of expected deaths.
Although the calculations are described above for each
subgroup of patients, the calculations may be more easily
carried out by computer for each individual patient. An exam-
ple calculation is shown below, for a group of 20 patients. For
reasons of emphasis and simplicity, hypothetical cases ("arti-
ficial data") are presented.
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(a) enter patients age at start date; due to small cell size, patients 0—14 years old are a single age group,
and rates for patients less than 20 years of age are not diagnosis specific (see Table 1)
(b) must be black or white; exclude patients of "other" race
(c) primary disease categories are diabetes, hypertension, glomerulonephritis, other
(d) must be the same date for all patients; prevalent patients only: exclude new patients who started
ESRD fewer than 90 days before this date
(e) enter end of study window, or the first of the following dates (occurring within the study
window): date of transplant, date of death, last date of follow-up
(f) calculated as number of days between start date and stop date (stop date — start date)
(g) rate per 1000 patient years for the given age, race, and diagnosis subgroup from attached Table 1
(h) calculated as (rate per 1000 patient years)/365,000
(i) calculated as Days at risk x Standard rate per patient day
(j) enter "I" if patient died during the study window, "0" if not
IMPORTANT: ONLY ENTER PREVALENT DIAL YSIS PATIENTS (NEVER TRANSPLANTED)
calculated by setting up a simple computer spreadsheet, for
example, Lotus or Excel. The age, race, and disease of each
patient within the locality are entered in separate columns (see
example, Table 2). Also entered for each patient is the start date
of the year being analyzed, and the stop date. This study will
that is, the "study window" (period of analysis) must be the
same for each patient. Since we are studying prevalent patients,
this criterion does not cause any difficulties (see section
Defining patient cohorts, below). We will use a one-year study
Table 2. Example for using mortality tables (Table 1) to compare local and national ESRD mortality rates
National rates
from
table standard
Patient Age Primary Start Stop Days at per 1000 per Expected Observed
ID at start Race disease date date risk pat. years pat. day deaths deaths
(a) (b) (c) (d) (e) (f) (g) (h) (i) (j)
1 76 White Hyperten. 31-Dec-87 4-Aug-88 217 470.7 0.00129 0.280 1
2 53 Black Hyperten. 31-Dec-87 31-Dec-88 366 127.7 0.00035 0.128 0
3 29 White Other 31-Dec-87 23-Nov-88 328 59.8 0.00016 0.054 1
4 37 White Other 31-Dec-87 31-Dec-88 366 66.4 0.00018 0.067 0
5 23 Black Diabetes 31-Dec-87 3-Jul-88 185 227.9 0.00062 0.116 0
6 65 Black Hyperten. 31-Dec-87 6-Aug-88 219 228.0 0.00062 0.137 1
7 72 White Glomer. 31-Dec-87 19-Sep-88 263 316.6 0.00087 0.228 1
8 70 Black Glomer. 31-Dec-87 4-Oct-88 278 301.2 0.00083 0.229 1
9 83 White Glomer. 31-Dec-87 19-Nov-88 324 466.3 0.00128 0.414 1
10 17 Black — 31-Dec-87 28-Dec-88 363 52.7 0.00014 0.052 1
11 51 Black Hyperten. 31-Dec-87 31-Dec-88 366 127.7 0.00035 0.128 0
12 54 White Diabetes 31-Dec-87 31-Dec-88 366 342.9 0.00094 0.344 0
13 61 White Diabetes 31-Dec-87 31-Dec-88 366 421.0 0.00115 0.422 0
14 78 White Other 31-Dec-87 3-Dec-88 338 402.3 0.0011 0.373 1
15 47 White Diabetes 31-Dec-87 31-Dec-88 366 322.9 0.00088 0.324 0
16 59 White Diabetes 31-Dec-87 13-Dec-88 348 386.9 0.00106 0.369 0
17 66 White Diabetes 31-Dec-87 24-Nov-88 329 454.5 0.00125 0.410 1
18 51 Black Diabetes 31-Dec-87 31-Dec-88 366 209.7 0.00057 0.210 0
19 83 White Hyperten. 31-Dec-87 17-Oct-88 291 592.0 0.00162 0.472 1
20 80 White Glomer. 31-Dec-87 31-Dec-88 366 466.3 0.00128 0.468 0
Total —> 5.223 10
(sum down expected deaths and observed deaths)
Calculation of chi-square statistic and standardized mortality ratio (SMR) Probability tablek
Chi-square: (observed — expected)2/expected < 0.05
= (10 — 5.223)2/5.223 see probability table---->
= 4.37
Caution, the chi-square test is only accurate when
the total expected deaths are greater than 5
SMR: observed / expected 91% higher mortality than
= 10/5.223 is expected from the natl.
= 1.91
Chi-Sq.
Statistic
P
value
>2.70 <0.100
>3.84 <0.050
>6.63 <0.010
>7.87 <0.005
>10.83 <0.001
k chi-sq. distribution,
degree of freedom
Example calculation have a start date of January 1, 1988. However, to include deaths
The expected number of deaths for a local population is easily that occur on January 1, 1988 the start date should be entered as
12/31/87. Note that all patients must have the same start date,
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window. Thus, the stop date for a patient is either the last day
of the year (December 31, 1988), the date of death, the date of
transplant, or the last day of follow-up on the patient, which-
ever occurs first.'
The time (in days) between any given patient's start date and
end date represents the patient's days at risk (or days of
follow-up) for that year. The spreadsheet will readily perform
date subtraction: subtracting the start date column from the
stop date column will yield days at risk. This result, labelled
"Days at risk" is entered in the column adjacent to the "Stop
date" column. The next column to enter for each patient is the
patient-specific national mortality rate from Table 1. This rate is
found by locating the cell on the table which corresponds to the
patient's age, race, and diagnosis. Since the rates in Table 1 are
expressed as deaths per year multiplied by one thousand
(deaths per 1000 patient years at risk), and we have calculated
time at risk in days for each patient, we must divide the rates by
365,000 (days in a year * 1000 years). The result of this calcu-
lation is entered in the next column labelled "Standard Rate."
Thus, in calculating this "standard" we are simply converting
the national rate in Table 1 from units of deaths per 1000 years
to units of deaths per day. The next column is the expected
number of deaths, which is calculated by multiplying the
standard rate by the days at risk: days (at risk) * deaths/day =
deaths (expected). This number approximates the probability of
dying in the given number of days at risk. The final column,
"Observed deaths" is a binary indicating whether the patient
died during the period at risk: enter 1 if the patient died during
the study window, 0 if not.
After entering all of the patient data, we sum down the
"Expected deaths" column and "Observed deaths" column to
get the Total expected deaths and the Total observed deaths—
these are the two numbers we want to compare. Note that the
expected number of deaths is not rounded off to an integer value
in the calculations.
With very large groups of patients, it may be easier to sort the
patients into the age-race-diagnosis subgroups found in the
table and calculate the aggregate days at risk separately for each
subgroup, instead of entering a line for each patient. For
example, if there are 6 Black, hypertensive patients between 50
and 54 years of age, calculate the total days at risk (the sum of
the individual days at risk) for these six patients and enter them
as one line on the spreadsheet.
Interpretation: Statistical signuIcance and relative risk
Differences between the observed and expected number of
deaths in a study group can arise by chance. The probability
that the observed discrepancy arose by chance is called the P
value. A small P value indicates that the difference is not likely
due to chance. The P value can be approximated by computing
the chi-square statistic (Obs-Exp)2/Exp. If the value of the
statistic is greater than 3.84 (see the partial table of the
chi-square distribution for 1 degree of freedom on Table 2), then
the approximate P value is less than 0.05. If the expected
For example, patients #5 and #16 in our example have stop dates
of prior to December 31, but they are not coded as having died—
actually #5 was transplanted on July 3, while #16 was lost to follow-up
(transferred out of the system) as of December 13.
number of deaths is less than 5, then the approximate P value
may not be a good approximation to the true P value and an
exact calculation should be made based on the Poisson distri-
bution [4]. If the P value is greater than 0.05, then the difference
is often labeled as "insignificant" and the difference is attrib-
uted as plausibly due to chance variations.
The ratio of the observed to the expected number of deaths is
a useful comparative summary, called the standardized mortal-
ity ratio (SMR). Thus a ratio of 1.10 indicates that the observed
mortality is 10% higher than expected from the national aver-
ages. Multiplying the overall (across age, race, and diagnosis)
national death rate by the SMR gives a standardized death rate
for the study group.
In the case of our example, a "typical" locality (that is, one
based on the national average) with this mix of patient ages,
races, and diseases could expect 5.3 patient deaths, yet 10
deaths actually occurred. The chi-square statistic (4.07) shows
that this difference is statistically significant at the 0.05 level.
The SMR is calculated as 10/5.22 = 1.91 or 191%, which
indicates that the number of deaths in this locality is 91% higher
than expected from the national norm. Thus, while the national
overall death rate is 250.6 deaths/1000 patient years at risk
(Table 1), the rate at this locality (adjusted for age, race, and
diagnosis) is 1.91 * 250.6 479 deaths/1000 patient years at
risk. The SMR and the standardized death rate are useful
because they allow for easy mortality comparisons among study
groups or between a study group and the national norm. The P
value from the chi-square statistic indicates if the difference in
rates is statistically significant.
Although the calculations are described above for patients
starting on January 1 of a specific year with the accumulation of
years of therapy stopping on December 31 of the same year, the
calculations need not extend for a full year. The study could be
based on any specific interval of time between 1987 and 1989;
for example June 1, 1988 to October 31, 1988. Because of the
way in which Table 1 was computed, the interval of time should
not substantially exceed one year in length. However, patients
may be entered into a second year if two prevalent years are
being analyzed. Further, Table 1 is based on prevalent ESRD
patients who had received dialysis therapy for at least 90 days
prior to the first of the year(S). Thus, only patients whose
dialysis started at least 90 days prior to the beginning of the
study interval should be included in the study; patients whose
therapy starts during the study interval or within 90 days of its
start should be excluded from the study. It should also be noted
that the rates in Table 1 are for patients on dialysis who have
never had a transplant, thus patients on dialysis with a prior
failed transplant should be excluded from the study.
Defining patient cohorts
The national death rates given here are derived from the
records of all dialysis patients in the USRDS who satisfied
certain criteria as of January 1 of a specified year. Those
patients were then followed until death, transplant, or the end
of the year. The same method of defining patient entry criteria
and follow-up must be used for each group of patients to be
studied with the methodology described here. The start and
stop dates of follow-up must be the same for all subjects in a
group, unless they die, are lost to follow-up, or receive a
transplant prior to the stop date.
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Patient entry criteria must be based on patient characteristics
as of the study start date and should not be based on charac-
teristics that develop during the follow-up. The only exception
to this rule arises if a patient is found during the follow-up
period not to have satisfied the entry criteria at the start date.
For example, a patient who recovers renal function during
follow-up should be excluded from analysis, since it is reason-
able to decide that the patient was not correctly classified on the
start date as requiring chronic renal replacement therapy. Our
experience indicates that it requires effort and careful thought
to identify the cohort of patients who are eligible on the start
date.
The national death rates are based on follow-up of patients
regardless of whether or not they transfer out of a facility. Thus,
patients who are transferred out of a facility should be followed
with regard to transplant and mortality status until the study
stop date. Mortality that occurs before the stop date should be
counted as observed mortality even if it occurs at another
facility, unless it occurs on the day of or after a transplant.
Although determination of patient status after transfer can be
difficult, it is important to do so because transferred patients
may be at especially high risk of death compared to patients
who do not transfer. Patient follow-up accounting should end
on the stopping date for all patients, even if their status is
known after that date.
The national death rates are based on follow-up of all dialysis
patients being treated on January 1 of a specific year, whose
ESRD therapy started at least 90 days prior to January 1. Thus,
patients who start therapy less than 90 days before the study
start date should not be included in the study. Similarly,
patients who start therapy during the study window should not
be added to the study. Only those days of patient follow-up
after the start date should be counted in the computations. In
particular, the follow-up during the 90 days, or any other time,
prior to the start date should not be counted in the follow-up
period.
The national death rates were based on the pooled results
from three cohorts of prevalent patients whose follow-up
started in 1987 through 1989, respectively. If the national
mortality rates do not change dramatically, then the national
death rates published here can also provide a useful norm for
patient follow-up during other recent periods, provided that the
method of follow-up is rigorously applied as described above.
Discussion
Although the methodology proposed here accounts for sev-
eral important aspects of patient mix and is thus an improve-
ment over comparisons of crude mortality rates, this method-
ology also has limitations. The numerical summary, the SMR,
should only be interpreted as an overall comparison value and,
as such, may obscure important details. For example, a facility
might provide relatively excellent care to one subgroup of
patients and relatively poor care to another. In such cases, the
reduced and excess mortality for the two subgroups tend to
balance and the resulting SMR could be close to 1.0. Similar
examples, based on differential mortality results for different
patient subgroups, show that it is often inappropriate to com-
pare 2 or more SMR values to each other [4]. The fact remains,
however, that an SMR that is significantly and substantially
greater than 1.0 indicates that more patients are dying than
would be expected based on national norms, at least in some
patient subgroups.
The method described allows two general types of compari-
sons. The first is a comparison of the mortality experienced by
a sample of ESRD patients with a specific age, race, and
diagnosis case mix (such as the patients at one dialysis unit) to
the national ESRD mortality rate for that particular case mix.
The second type of comparison is between the mortality for a
specific age-race-diagnosis group (for example, all the 45 to 50
year-old, White, diabetic patients within a network) and the
mortality experienced by that age-race-diagnosis group nation-
ally.
More specifically, comparisons to the national norm could be
useful for testing a clinical hypothesis. The mortality for pa-
tients receiving a specific type of dialytic therapy could be
evaluated to determine whether those patients had higher or
lower mortality than expected based on national mortality rates
for comparable patients. The results of such a comparison could
be useful for deciding whether or not to carry out a more formal
evaluation of the therapy using a randomized clinical trial
study.
Comparisons to the national norm could be useful for identi-
fying subgroups of patients who respond differently to treat-
ment than does the general population of ESRD patients.
Evaluation of the mortality among patients who have a distin-
guished characteristic, such as diet, would show whether mor-
tality is associated with that characteristic. Although useful for
hypothesis generation, no causal mechanism can be definitely
established by such a comparison, because the patients might
also be distinguished with regard to other characteristics than
the one used to identify the group.
The national norm is just the "average" and should not be
misinterpreted as a standard that represents ideal care. If a
mortality difference is found to be significant (that is, unlikely to
have arisen by chance) and important (large enough to have
clinical importance), one must then try to identify the reasons
for the difference. Isolating the specific reason for a difference
may be difficult when the comparison group is as general as the
entire USRDS Medicare ESRD patient population. The next
step might be a more focused comparison between two or more
specific subgroups of patients. Thus, while a comparison to the
national norm is a useful tool for identifying mortality differ-
ences among patients, it is generally only a first step toward
understanding causal mechanisms underlying these mortality
differences.
Utilization of the methodology described here requires strict
adherence to the inclusion and follow-up criteria described in
the Methods. Any deviation may lead to erroneous results. For
example, if patients transferred to hospital were analyzed as
alive and lost to follow-up on that date of transfer, then the
survival among the remaining patients would appear to be
better than expected, since hospitalized patients have an ele-
vated risk of death. Our exclusion from analysis of patients with
recovered renal function is an arbitrary one, but is designed to
reduce the variability due to different criteria for distinguishing
between ESRD and prolonged acute renal failure.
An important advantage of the methodology described here is
its application of adjustments for age, race, and diagnostic
groups, combined with its relative simplicity. Thus, individual
dialysis facilities can compare their outcomes with adjusted
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national averages, independent of government and other review
agencies. International comparisons of mortality can also be
made using this methodology though interpretation of results
may be difficult due to vast differences in transplantation rates.
Easily calculated local to national comparisons may lead to
earlier interventions once the existence of relatively high mor-
tality rates are identified, or, upon the observance of low
mortality rates, the identification and broader utilization of
successful treatment techniques that improve patient outcomes.
There are many important determinants of survival that are
not accounted for by this methodology. More detailed adjust-
ments for patient condition and years of ESRD therapy would
be useful but are also more difficult to implement. The adjust-
ments made with the methodology here control for some of the
major factors influencing mortality rates—patient age, race, and
primary disease causing ESRD—but they are only a first step in
a careful evaluation of comparative mortality rates.
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